B
Bull
Bull · 25%SAGE
$14.56
Scenario price
$8.680
-0.020 (-0.23%)At close
Loading chart…
- High
- 8.740
- Open
- 8.740
- VWAP
- 8.70
- Vol
- 22.70M
- Mkt Cap
- 643.35M
- Low
- 8.680
- Amount
- 197.48M
- EV/EBITDA, TTM
- 0.42
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Analyst Ratings (15)
0.00% downside
Buy
14 Buy
1 Hold
0 Sell
Current: 8.68
Low
5.00
Average
8.68
High
12.00
Scotiabank
Sector Perform
$9.20
2025-07-07
Scotiabank
2025-07-07
Price Target
$9.20
Sector Perform
JPMorgan
Neutral
$11
2025-06-22
JPMorgan
2025-06-22
Price Target
$11
Neutral
Baird
Neutral
$9
2025-06-21
Baird
2025-06-21
Price Target
$9
Neutral
Piper Sandler
Neutral
$9
2025-06-18
Piper Sandler
2025-06-18
Price Target
$9
Neutral
BofA
No Rating
$12
2025-06-18
BofA
2025-06-18
Price Target
$12
No Rating
Valuation Metrics
The current forward P/E ratio for SAGE Therapeutics Inc (SAGE) is -1.96, compared to its 5-year average forward P/E of -3.49.
Alphio AI Price Scenarios for SAGE
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.506-24Yahoo FinanceSage Potash Prepares for 2026 Drilling Program
8.507-31NewsfilterSupernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
8.507-28NewsfilterSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
9.007-25NASDAQ.COMBiogen's ZURZUVAE Wins EMA Panel Backing For Postpartum Depression Treatment
9.007-24GlobenewswireZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
SAGE FAQ — answered by Alphio AI
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
15 analysts cover SAGE: 14 rate it Buy, 1 Hold and 0 Sell. The average price target is 8.68.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.